Search

Displaying results 7281 - 7290 of 10000 in total
  1. Drug

    D-JNKI-1

    go.drugbank.com/drugs/DB05660
    Investigational

    A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of ox...

  2. Drug

    Botulinum toxin type B

    go.drugbank.com/drugs/DB00042
    Approved

    The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex.

  3. Drug

    Cilobradine

    go.drugbank.com/drugs/DB20039
    Investigational

    Cilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine). … The usage of the INN stem '-bradine' in the name indicates that Cilobradine is a bradycardic agent.

  4. Drug

    Resomelagon

    go.drugbank.com/drugs/DB21579
    Investigational

    Resomelagon is under investigation in clinical trial NCT06917001 (Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)). … The usage of the INN stem '-melagon' in the name indicates that Resomelagon is a non-peptidic melanocortin receptor agonist.

  5. Drug

    Melengestrol

    go.drugbank.com/drugs/DB11529
    ExperimentalVet approved

    An acylated derivative, melengestrol acetate, is used as a growth promoter in animals.

  6. Drug

    BMS-919373

    go.drugbank.com/drugs/DB15047
    Investigational

    BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).

  7. Drug

    Iratumumab

    go.drugbank.com/drugs/DB05550
    Investigational

    In phase I/II clinical trials for treatment of CD30+ lymphomas.

  8. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  9. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  10. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines.